Hot Life Science Investor Mandate 1: US Based Venture Arm of Chinese Family Office Seeking Preclinical Biologic Opportunities

~ Next Phase Admin ~ Leave a comment

A private investment group that was founded by a single family out of Hong Kong has four operations based in Shanghai, Beijing, Hong Kong and the US. The US-based venture investment arm is actively seeking new investments in the life sciences across the US, and it occasionally invests in companies in Europe. The group focuses on pre-clinical and clinical stage companies. The investment size will vary and typically it ranges from $2 million -$10 million. The group has no set number of allocations over the next 6-9 months.

In the life sciences the firm is looking for new investments primarily in the biotech therapeutics sector. The group will also look at medical devices and diagnostics opportunities, however, which are not their current focuses. For therapeutics, the group is most interested in biologics. The group invests in a variety of therapeutic areas with a focus on oncology. The group generally invests in pre-clinical stage companies without clinical data, and it also syndicates with other investors for clinical-stage investments.

The group invests in privately held life science companies. The group is generally not interested in commercial-stage companies.

If you are interested in more information about this investor and other investors tracked by LSN, please emailĀ mandates@lifesciencenation.com

Hot Life Science Investor Mandate 2: Large Pharma Company Seeking Partnerships in Cardio, Oncology, Virology and More

~ Next Phase Admin ~ Leave a comment

A large pharmaceutical company with offices worldwide uses a wide variety of structures in order to engage with innovative early-stage companies, including in-licensing, equity investments, options, collaborations, and acquisitions. The firm is currently looking to form new partnerships with early stage companies worldwide.

The firm is interested in therapeutic assets in the following key disease areas: cardiovascular, fibrosis, immunology, oncology, virology, and genetically-defined diseases. The firm can invest at any stage of development, from very early discovery-stage assets through to marketed products. The firm is open to any technological approach, but is only interested in novel drugs; biosimilars and reformulations are not of interest.

If you are interested in more information about this investor and other investors tracked by LSN, please emailĀ mandates@lifesciencenation.com

Hot Life Science Investor Mandate 3: Taiwanese PE Firm Seeking Global Biopharmaceutical, Medtech, and Diagnostic Opportunities

~ Next Phase Admin ~ Leave a comment

A life science dedicated PE fund of a Taiwanese company engaged in leasing, finance, and investment businesses is currently seeking new opportunities. The fund prefers to invest in early stage companies but is also interested in growth-expansion stage companies. The fund can invest up to USD 30 million or more per company. The fund will focus on companies founded and operated in the Greater China region (60% of fund allocation). The fund is also interested in opportunities from Europe (especially in Switzerland, Germany, and the UK) as well as from the US.

The fund seeks to invest in biopharmaceuticals and medical technologies. In biopharma, the fund focuses on novel drugs, drugs with new indication/dosage form, biosimilar, and API for cancer drug. The fund looks for proprietary drug discovery or development technologies that are able to build a multi-product pipeline and products that address large unmet medical needs. For medical technologies, the firm focuses on molecular IVD test/next-generation sequencing, monitor & diagnostics system, invasive devices, cosmetics/plastic surgery, ICT medical device, and combination products with Greater China market potential. The firm looks for new and innovative technologies that can increase performance, lower cost or open up new business models.

The fund prefers to invest in early stage companies and generally acquires a minority stake in the company. However, the fund does not rule out the possibilities of acquiring a controlling stake if the strategic value exists.

If you are interested in more information about this investor and other investors tracked by LSN, please emailĀ mandates@lifesciencenation.com

Hot Life Science Investor Mandate 4: A Foundation for Childrenā€™s Health Seeking to Make First Venture Investments

~ Next Phase Admin ~ Leave a comment

A foundation formed to improve the health and quality of life for children has recently begun looking to make equity investment in early stage companies. The foundationā€™s programs supports pediatric researchers who work in nonprofit academic, medical or research institutions within the six New England states. The foundation is currently developing a new financial vehicle to make program related investment in commercial companies developing technologies that can improve childrenā€™s health. The foundation expects to make 1-2 equity allocations of $200,000 in the current year and is seeking opportunities globally.

The foundation is looking for high impact innovations in childrenā€™s health with a special interest in neonatal care and pediatric neurology. The foundation is agnostic to technology sectors. The foundation is interested in single assets as well as platform technology that can be applied to the pediatric field.

The foundation seeks privately held companies with competent management teams with sector expertise.

If you are interested in more information about this investor and other investors tracked by LSN, please emailĀ mandates@lifesciencenation.com

Innovation In Spotlight at RESI

~ Next Phase Admin ~ Leave a comment

ByĀ Shaoyu Chang,Ā MD, MPH, Ā Senior Research Analyst, LSN

Shaoyu 10*10

Life Science Nation unveiled the finalists that were hand-picked to enter the RESI Boston Innovation Challenge: an exciting group of innovative life science companies in therapeutics, diagnostics, medical devices, and healthcare information technology (HC IT).

As RESI returns to the Boston-Cambridge life science hub, the Innovation Challenge has received unprecedented amount of interest. The RESI scientific team has gone through rigorous review and independently hand-picked top companies, who will showcase their innovations in the RESI exhibition hall.

Many of the selected companies emerged from top-tier universities, have obtained initial validation through government grants or nonprofit organizations, have established external collaborations, and are on the path to commercializing their research and technology. ā€œThe RESI Challenge is shaping up to be one of the best group of innovators with the latest technology across the health care domain,ā€ says Dennis Ford, LSNā€™s CEO.

RESI Boston Innovation Challenge features a diverse mix of technology sectors. Biopharmaceutical startups make up the largest sector. These companies leverage advanced cell therapy, novel molecules, and untapped pathways to combat cancer, immune disorders and infectious diseases. The competition also features advanced diagnostic, medical device and HC IT technologies, from novel molecular tracers that monitor T cells in immunotherapy, to analytical software that improves magnetic resonance imaging.

ā€œRESI has become a beacon that attracts scientist entrepreneurs to showcase their latest products and services to global early stage life science investors,ā€ says Dennis. LSN expects over 200 investors at RESI Boston. ā€œInvestors use this vehicle to keep abreast of the latest technology and teams that are surfacing in the life science arena.ā€

The companies will be given a presentation space in the RESI exhibition hall, where they will be able to engage in in-depth, face-to-face conversation with investors and strategic partners throughout the one-day event. All conference attendees will be given ā€œRESI Cashā€ to invest in the most attractive companies in their mind. At the end of the conference, the top three companies receiving the most RESI Cash will be announced winners of RESI Innovation Challenge.

The full list of RESI Innovation Challenge companies can be found below.

Chapter 13: “Straight Talk About Finding, Vetting, and Closing Capital”

~ Next Phase Admin ~ Leave a comment

By Lucy Parkinson, Senior Research Manager, LSN

Following the overview of the fundraising process in Chapter 12, we get into some of the nitty-gritty areas and explore a few common pitfalls and how to avoid them. Chapter 13 discusses the importance of getting on the road or hitting the phone to engage with relevant investors, and why it’s important to ensure that all the investor prospects you speak with are kept in context regarding the deal. Finally, the chapter explores how to prioritize your prospects to use your runway time most effectively while raising money.

Click here to download/print the chapter PDF

Next week, LSN will bring you the final chapter, “Thirty-One Tips For Effective Fundraising”.

Enjoyed the preview? Buy now fromĀ Amazon.comĀ orĀ Barnes & Noble

Bookcover-Front

Venture Philanthropy Panel Announcement: RESI Boston

~ Next Phase Admin ~ Leave a comment

By Michael Quigley, Director of Research, LSN

mike-2

Venture philanthropy has become an increasingly significant source of capital for the earliest stages of company development in the life science space. Often looking to help bridge the gap between angel and venture capital financing, these groups have improved patient outcomes as their bottom line and look to use their financial returns from investments to improve that metric further. Financing is far from the only thing venture philanthropy groups can bring to an early stage company; they can often supply access to patients and experts in their field, access to tissue banks, and connections to donors.

At RESI in Boston this Sept. 16th we will be bringing together 5 experts in the venture philanthropy space to discuss the various ways that they can work with and help early stage life science companies.

In a panel moderated by Chris de Souza, Director of Broadview Ventures, the audience will hear from:

If venture philanthropy investment is part of the plan to get your company funded or to its next inflection point, this panel presents a great opportunity to broaden your network while expanding your understanding of these organizations.